Fibrinogen Activity
Also known as: Clottable Fibrinogen, Factor I Activity
Use
Diagnosis of homozygous and heterozygous fibrinogen deficiency as well as dysfibrinogenemia; diagnosis of disseminated intravascular coagulation;6-8 fibrinogen levels can be used to assess the effectiveness of thrombolytic therapy.9
Special Instructions
If the patient's hematocrit exceeds 55%, the volume of citrate in the collection tube must be adjusted according to coagulation collection procedures. Proper blood to anticoagulant ratio should be maintained by filling the tube to completion and mixing gently by inversion.
Limitations
Fibrinogen levels can become significantly increased in conditions involving tissue damage, infection, or inflammation and may be elevated in smokers, pregnant women, and women taking oral contraceptives. Diminished fibrinogen levels can occur in advanced liver disease. High levels of heparin, direct thrombin inhibitors, or fibrin breakdown products may falsely lower fibrinogen activity levels.
Methodology
Other
Biomarkers
LOINC Codes
- 3255-7
- 3255-7
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
4.5 mL, 2.7 mL, 1.8 mL
Minimum Volume
90% of full draw
Container
Blue-top (sodium citrate) tube
Collection Instructions
Collect blood in a blue-top tube containing 3.2% buffered sodium citrate. Fill tube to completion and mix by gentle inversion.
Storage Instructions
If testing cannot be completed within 24 hours, centrifuge for at least 10 minutes at 1500xg, transfer plasma to a PP transpak frozen purple tube, freeze immediately, and maintain frozen until tested.
Causes for Rejection
Clotted specimen; gross lipemia or hemolysis; tubes <90% full; improper labeling; specimen collected in tube other than 3.2% citrate
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 day |
| Frozen | 14 days |